[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100439829":3},{"organization":4,"outcomesModule":7,"designInfo":19,"detailedDescription":18,"studyPopulation":22,"armGroups":18,"interventions":18,"overallOfficials":18,"centralContacts":23,"locations":29,"responsibleParty":46,"collaborators":48,"id":52,"slug":18,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":18,"studyType":65,"phases":18,"briefSummary":66,"conditions":67,"keywords":18,"overallStatus":32,"whyStopped":18,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Centre Oscar Lambret","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":15,"otherOutcomes":18},[9,13],{"measure":10,"description":11,"timeFrame":12},"Antitumor activity of the CAR-macrophages against organoids from HER2 negative, HER2 low and HER2 positive breast cancers","Measurement of the phagocytic capacity","24 months",{"measure":14,"description":11,"timeFrame":12},"Antitumor activity of the CAR-macrophages compared to non-modified macrophages",[16],{"measure":17,"description":11,"timeFrame":12},"Antitumor activity of the CAR-macrophages against organoids from early and advanced breast cancers patients",null,{"allocation":18,"interventionModel":18,"interventionModelDescription":18,"primaryPurpose":18,"observationalModel":20,"timePerspective":21,"maskingInfo":18},"COHORT","PROSPECTIVE","This is a cohort study conducted in breast cancer patients requiring a surgery or a tumor biopsy as part of their care.",[24],{"name":25,"role":26,"phone":27,"phoneExt":18,"email":28},"Nawale HAJJAJI, MD PhD","CONTACT","+33 320295910","n-hajjaji@o-lambret.fr",[30],{"facility":31,"status":32,"city":33,"state":18,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Oscar Lambret Center","RECRUITING","Lille","59000","France","FR",{"type":38,"coordinates":39},"Point",[40,41],3.05512,50.63391,{"lat":41,"lon":40},[44],{"name":45,"role":26,"phone":18,"phoneExt":18,"email":18},"Nawale Hajjaji, MD, PhD",{"type":47,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[49],{"name":50,"class":51},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV","100439829",false,"NCT05007379","Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids","Cohort Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids (CARMA)","CARMA","Inclusion Criteria:\n\n* Male or female aged 18 years or more\n* Histologically confirmed breast cancer at any stage\n* Requiring surgery or tumor biopsy as standard of care\n* Any or no systemic treatment\n* Signed informaed consent\n* Health insurance coverage\n\nExclusion Criteria:\n\n* Opposed to biospecimen collection","ALL","18 Years","100 Years",{"count":63,"type":64},100,"ESTIMATED","OBSERVATIONAL","Cell-based immune therapy using modified macrophages is a promising therapeutic approach in breast cancer. The objective of this cohort study is to collect tumor samples to develop patients' derived organoids to test the antitumor activity of newly developed CAR-macrophages. Other biological samples will be collected such as blood to analyze the host inflammatory status.",[68],"Breast Cancer","2026-03-16",{"date":71,"type":72},"2026-03-18","ACTUAL",{"date":74,"type":72},"2021-11-02",{"date":76,"type":64},"2027-12-01",{"name":5,"class":6},1]